Overture Life Secures $57M in Total Funding and Earns U.S. CLIA License to Deliver Reliable, Scalable IVF Automation

Overture Life 获得总计 5700 万美元融资并取得美国 CLIA 许可证，以提供可靠且可扩展的体外受精自动化解决方案。

Overwater Ventures, GV, and Khosla Ventures invest in a rigorous clinical approach that raises throughput for fertility clinics, expands access, and empowers women to plan on their own terms

Overwater Ventures、GV 和 Khosla Ventures 投资了一种严格的临床方法，这种方法提高了生育诊所的效率，扩大了获取渠道，并赋予女性按自己的意愿进行规划的权利。

PALO ALTO, Calif., April 24, 2025-- Overture Life today announced a $20.6 million strategic round, bringing its total funding to $57 million from leading industry investors, to support additional clinical research and product development designed to make IVF affordable to more people. The company is also announcing its newly achieved CLIA (Clinical Laboratory Improvement Amendments) license in the United States to meet federal clinical laboratory standards for m|z, its AI-powered, non-invasive metabolomic test for embryo selection.

加利福尼亚州帕洛阿尔托，2025年4月24日——Overture Life今日宣布完成2060万美元的战略融资，截至目前，其总融资额已达到5700万美元，投资方为行业领先投资者，资金将用于支持更多临床研究和产品研发，旨在让体外受精（IVF）技术惠及更广泛的人群。公司还宣布已获得美国CLIA（临床实验室改进修正案）认证，以满足其AI驱动的无创代谢组学胚胎选择测试m|z的联邦临床实验室标准。

These latest milestones reinforce Overture’s commitment to demonstrating scientific rigor, securing regulatory support, and prioritizing patient safety. They also pave the way for the launch of DaVitri, an advanced embryology platform that automates egg freezing (vitrification) and embryo warming under reproducible, data-driven protocols..

这些最新的里程碑进一步证明了 Overture 致力于展示科学严谨性、获得监管支持以及优先考虑患者安全的承诺。它们还为推出 DaVitri 这一先进的胚胎学平台铺平了道路，该平台可在可重复且数据驱动的协议下自动完成卵子冷冻（玻璃化）和胚胎解冻过程。

For too long, IVF has been inaccessible for too many people, with inefficiencies driving up costs. Since 2017, Overture has modernized the core technology involved in IVF through proprietary software, robotics, microfluidics and rigorous scientific validation, documented in peer-reviewed publications, scientific presentations, and, most importantly, two healthy, live births resulting from the use of its technology..

长时间以来，由于效率低下的问题推高了成本，使得太多人无法接受体外受精（IVF）治疗。自2017年以来，Overture通过专有软件、机器人技术、微流体技术以及严格的科学验证，现代化了IVF所涉及的核心技术。这些成果已被记录在同行评审的出版物、科学报告中，最重要的是，已有两个使用其技术诞生的健康婴儿。

Its newest platform, DaVitri, addresses essential lab steps that historically rely on manual precision. By standardizing these procedures with precise timing and controlled cryoprotectant exposure, DaVitri has demonstrated improved oocyte survival rates in early clinical evaluations, potentially reducing repeated IVF cycles that can drain resources and emotional energy.

其最新的平台 DaVitri 解决了历史上依赖手动精确操作的关键实验室步骤。通过使用精确的时间控制和受控的冷冻保护剂暴露来标准化这些程序，DaVitri 在早期临床评估中已显示出提高了卵母细胞的存活率，可能减少重复的体外受精周期，从而节省资源和情感精力。

In addition, its streamlined, gentler freezing process helps clinics maintain consistent lab results, allowing embryologists to handle more cycles without compromising quality..

此外，其简化、更温和的冷冻过程有助于诊所保持一致的实验室结果，使胚胎学家能够处理更多的周期而不影响质量。

“This new funding allows us to accelerate our expansion of IVF capabilities and demonstrates the value of operating within a CLIA-licensed laboratory environment, highlighting not only our technological leadership but also our commitment to the highest standards of clinical validation,” said Hans Gangeskar, CEO of Overture Life.

“这笔新的资金使我们能够加快扩展试管婴儿技术的能力，并证明了在CLIA认证的实验室环境中运营的价值，这不仅彰显了我们的技术领导地位，也体现了我们对临床验证最高标准的承诺，”Overture Life首席执行官汉斯·甘格斯卡尔表示。

“DaVitri has already shown potential to significantly increase clinical throughput while ensuring reproducibility in critical freezing and warming processes, allowing embryologists to prioritize personalized patient care. Our approach is rigorous and evidence-based because we understand how deeply personal this journey is for families.”.

“DaVitri 已经展现出在确保关键的冷冻和解冻过程的可重复性的同时显著提高临床通量的潜力，使胚胎学家能够优先提供个性化的患者护理。我们的方法严谨且基于证据，因为我们深知这段旅程对家庭而言是多么个人化。”

“Automation and standardization in the embryology lab is an exciting step towards optimizing efficiency and efficacy in IVF. It allows us to deliver consistent and excellent care, while still giving us the flexibility to fine-tune protocols for our patients,' said Serena H. Chen, MD, a Reproductive Endocrinologist at CCRM Fertility of NJ.

“胚胎学实验室的自动化和标准化是优化体外受精效率和效果的激动人心的一步。它使我们能够提供始终如一的优质护理，同时仍然给予我们根据患者需求微调方案的灵活性，”新泽西CCRM生育中心的生殖内分泌学家Serena H. Chen医学博士说道。

“We're very excited about the potential to serve more patients by increasing lab capacity without sacrificing quality.”.

“我们对通过增加实验室容量而不牺牲质量来服务更多患者感到非常兴奋。”

This strategic round, supported by Overwater Ventures, GV (formerly Google Ventures), and Khosla Ventures, reflects a deep conviction in Overture’s science-led mission: to expand fertility access by making IVF labs more reproducible, efficient, and ultimately less cost-intensive.

这家战略轮融资得到了 Overwater Ventures、GV（前身为 Google Ventures）和 Khosla Ventures 的支持，反映了对 Overture 科学引领使命的深刻信念：通过使试管婴儿实验室更具可重复性、效率更高，并最终降低成本，来扩大生育能力的获取途径。

“Fertility intersects healthcare, economics, and the most personal of human wishes,” said Kristina Simmons, Founder and Managing Partner at Overwater Ventures. “Women have long faced irreversible biological timelines, and by making egg freezing cheaper, easier, and more clinically effective and predictable, it allows women and families to regain choice and opportunity.

“生育能力与医疗保健、经济以及人类最个人的愿望交织在一起，”Overwater Ventures创始人兼管理合伙人克里斯蒂娜·西蒙斯表示。“女性长期以来一直面临着不可逆的生物时间表，通过让卵子冷冻变得更便宜、更容易、更具有临床效果和可预测性，这使女性和家庭能够重新获得选择和机会。”

Overture’s platform provides a precise alternative that can run more cycles successfully, enabling women to freeze their eggs or pursue IVF on their own terms and timelines. By fitting the embryology protocols into a compact, desk-sized system, Overture is reinventing egg freezing and IVF for a better patient experience and strong, clinically reproducible outcomes with proven science.”.

Overture的平台提供了一种精确的替代方案，可以成功运行更多周期，使女性能够按照自己的条件和时间表冷冻卵子或进行体外受精。通过将胚胎学操作流程整合到一个紧凑的、桌面大小的系统中，Overture正在重塑卵子冷冻和体外受精技术，以带来更好的患者体验以及基于可靠科学的强大且临床可重复的结果。

About Overture Life

关于Overture Life

Overture Life integrates engineering, reproductive medicine, and regulatory-grade validation to modernize embryology lab procedures, particularly egg freezing and embryo handling, in ways that lower repeated cycles, increase throughput, and reduce the overall cost of IVF. With R&D in Spain and active U.S.

Overture Life整合了工程学、生殖医学和符合监管标准的验证，以现代化胚胎学实验室程序，特别是卵子冷冻和胚胎处理，从而减少重复周期、提高处理量并降低体外受精的总体成本。公司在西班牙进行研发，并在美国积极开展业务。

operations, including a CLIA-licensed laboratory for non-invasive embryo selection, Overture unites robotics, analytics, and clinical rigor to deliver tools that clinics and patients can trust. The company’s DaVitri platform aims to boost reliability and consistency in IVF, giving women and families worldwide more control over their fertility timelines.

运营项目，包括持有CLIA认证的非侵入性胚胎筛选实验室，Overture结合了机器人技术、分析工具和临床严谨性，提供诊所和患者可以信赖的工具。该公司的DaVitri平台旨在提高体外受精的可靠性与一致性，让全球女性和家庭更能掌控自己的生育时间规划。

Overture’s backers include Overwater Ventures, GV, Khosla Ventures, Octopus Ventures and others committed to advancing the future of fertility..

Overture 的支持者包括 Overwater Ventures、GV、Khosla Ventures、Octopus Ventures 和其他致力于推动生育未来发展的机构。

Contact:

联系：

Media Contact

媒体联系人

overture@consortpartners.com

序曲@财团合作伙伴.com